The French pharmaceutical giant and his British GSK partner, who have not yet made public the studies on which these results are based, reported that their vaccine had been effective in avoiding any hospitalization related to CIVID-19.
Le Monde
The French pharmaceutical giant Sanofi announced on Wednesday 23 February of large-scale positive results for its anti-Covid vaccine, developed with the British GSK, a project that results with nearly one year late following multiple reports. .
In a statement, Sanofi and its British GSK partner stated that they would “seek regulatory approval from their VVID-19” vaccine in the United States and the European Union, at the end of Phase 3 tests carried out with thousands of people.
The laboratories, which have not yet made public the studies on which these results are based, reported that this vaccine was effective in avoiding any hospitalization of CVIV-19. They also reported a slightly greater efficiency than 50% against all infections causing symptoms.
The end of a long sheet
It’s “comparable to the effectiveness of vaccines already available,” said Sanofi, in a context where all existing vaccines lost over time their effectiveness against contamination, particularly since the boom End 2021 of Omicron Variant.
This announcement, which paves the way for a place on the next market for a green light of the health authorities, marks the culmination of a long sheet for Sanofi, which recorded several setbacks in its vaccine projects Anti-Covid.
The French group had to repel its calendar twice as to this vaccine, which he originally hoped for making available before the mid-2021. He first registered a six-month delay, because of a dosage problem, then again ended because of the difficulties in finding people never contaminated to conduct reliable tests.
Less innovative technology than messenger RNA
Sanofi has furthermie another Anti-Covid vaccine project, based on messenger RNA technology like those developed by Pfizer / Biontech and Moderna, already at the heart of immunization campaigns in multiple Western countries.
As for the vaccine on which the French group is now concentrated, it uses a slightly less innovative technology, based on a recombinant protein. This is also the case of the American Vaccine Novavax, who will begin to be distributed in France.
The health authorities hope that these vaccines will be able to be well received by the suspicious people towards the messenger RNA technology, while insisting that these fears are unfounded.